Marco Meglio

In July, the FDA is expected to make a decision on lecanemab (Leqembi), an antiamyloid therapy previously approved under the accelerated approval pathway, for a potential traditional approval for early-stage Alzheimer disease.

Investigators observed significant correlations between processing speed and arterial stiffness among patients with multiple sclerosis, but not in healthy controls.

Over the 96-week treatment period, ublituximab-treated patients outperformed teriflunomide-treated patients on several domains of the Fatigue Impact Scale.

Despite similar proportion of females and ever-smokers, age of onset of multiple sclerosis was significantly earlier for Latinx patients compared with White non-Latinx individuals.

Investigators observed significant decreases in Modified Fatigue Impact Scale and Fatigue Severity Scale with the low-fat diet in relation to controls.

Cornelia Drees, MD, senior associate consultant, Department of Neurology, Mayo Clinic, discussed the potential of microburst vagus nerve stimulation as a more targeted treatment for drug-resistant epilepsy.

Tiffany Braley, MD, MS, associate professor of neurology, University of Michigan, provided insight on the challenges of fatigue in multiple sclerosis, and where research efforts should be directed to.

The research, which highlighted stressors occurring in both childhood and adult stages contributing to MS disability, could inform conversations regarding stress reduction techniques for patients with MS.

Kathy Zackowski, PhD, OTR, associate vice president of research at the National MS Society, provided insight on the ongoing efforts to treat progressive MS, including strategies to develop remyelinating treatments.

On multiple phase 3 trials, treatment with STS101 resulted in numerical differences on primary outcome measures of pain freedom and freedom from the most bothersome symptoms.

Pitolisant, a therapy approved for patients with narcolepsy, is currently being assessed in 200 individuals with idiopathic hypersomnia, with change in excessive daytime sleepiness as the primary outcome.

Over a 72-week treatment period, vatiquinone showed significant impacts on bulbar and upright stability subscales of the modified Friedreich Ataxia Rating Scale score.

Investigators observed similar rates of intracranial hemorrhage for patients with minor stroke on a dual thrombolytic treatment vs those who received alteplase alone.

In a 6-month trial, more than 85% of adults on CBD showed significant reduction in the number of monthly seizures, suggesting this treatment may be an effective adjuvant option.

Thirty days after treatment, a primary-outcome event occurred in 2.9% of those in the early-treatment group and 4.1% of those in the later-treatment group.

Using trials selected by amyloid positivity, amyloid-targeting therapies had slightly greater efficacy in APOE ε4 carriers than in noncarriers.

Robust, sustained reductions in key pharmacodynamic biomarker were observed; however, this did not lead to functional benefits on any of the scales used in the trial.

Submitted under the accelerated approval pathway, if approved, SRP-9001 would become the first marketed gene therapy specific for Duchenne muscular dystrophy.

The senior associate consultant in the Department of Neurology at Mayo Clinic provided insight on an early feasibility study on the clinical impact of microburst vagus nerve stimulation in patients with drug-resistant epilepsy.

Females with episodic migraine had higher interictal CGRP concentrations in plasma and the tear fluid during menstruation than females without migraine.

Clinically relevant effect sizes were observed, with those in the highest Dietary Inflammatory Index quartile having relapse risk 2.45 times higher than those in the lowest quartile.

Findings showed that greater average daily step count was significantly correlated with greater C2-C3 spinal cord gray matter areas, total cord area, and cortical gray matter volume.

Asudexian is currently being assessed in a large-scale phase 3 program expected to comprise more than 27,000 patients with atrial fibrillation across over 40 countries.

To date, in the largest series of patients treated with lacosamide after first-line treatment failure, pain relief was achieved in 66% of patients, with a relatively low proportion of mild adverse events.

The phase 1/2 MARINA trial assessed the activity of AOC 1001 across key biomarkers, including spliceopathy, an important biomarker for myotonic dystrophy type 1, and knockdown of DMPK mRNA.

Treatment with valbenazine at doses of up to 80 mg once per day significantly improved chorea, as demonstrated by the mean change in UHDRS Total Maximal Chorea scores.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Berry, MD, PhD. [LISTEN TIME: 14 minutes]

Over a 4-month treatment period, the agent was well tolerated, with patients showing no significant changes in ADAS-Cog or CDR-SB scores, indicating no cognitive decline.

Comprised of the recharge-free Proclaim SCS family and the rechargeable Eterna SCS platform, the approval for Abbott’s spinal cord stimulation system was backed by the large-scale, DISTINCT study.

Findings from the 12-week study showed a significant decrease in total number of new gadolinium-enhancing lesions in patients with relapsing MS on fenebrutinib relative to placebo.